The impact of lowering the study design significance threshold to 0.005 on sample size in randomized cancer clinical trials
© The Author(s) 2023..
The proposal of improving reproducibility by lowering the significance threshold to 0.005 has been discussed, but the impact on conducting clinical trials has yet to be examined from a study design perspective. The impact on sample size and study duration was investigated using design setups from 125 phase II studies published between 2015 and 2022. The impact was assessed using percent increase in sample size and additional years of accrual with the medians being 110.97% higher and 2.65 years longer respectively. The results indicated that this proposal causes additional financial burdens that reduce the efficiency of conducting clinical trials.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:8 |
|---|---|
| Enthalten in: |
Journal of clinical and translational science - 8(2024), 1 vom: 15., Seite e9 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Leung, Tiffany H [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Clinical trial |
|---|
| Anmerkungen: |
Date Revised 24.02.2024 published: Electronic-eCollection Citation Status PubMed-not-MEDLINE |
|---|
| doi: |
10.1017/cts.2023.699 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM368749290 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM368749290 | ||
| 003 | DE-627 | ||
| 005 | 20240229150325.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240222s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1017/cts.2023.699 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1304.xml |
| 035 | |a (DE-627)NLM368749290 | ||
| 035 | |a (NLM)38384917 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Leung, Tiffany H |e verfasserin |4 aut | |
| 245 | 1 | 4 | |a The impact of lowering the study design significance threshold to 0.005 on sample size in randomized cancer clinical trials |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Revised 24.02.2024 | ||
| 500 | |a published: Electronic-eCollection | ||
| 500 | |a Citation Status PubMed-not-MEDLINE | ||
| 520 | |a © The Author(s) 2023. | ||
| 520 | |a The proposal of improving reproducibility by lowering the significance threshold to 0.005 has been discussed, but the impact on conducting clinical trials has yet to be examined from a study design perspective. The impact on sample size and study duration was investigated using design setups from 125 phase II studies published between 2015 and 2022. The impact was assessed using percent increase in sample size and additional years of accrual with the medians being 110.97% higher and 2.65 years longer respectively. The results indicated that this proposal causes additional financial burdens that reduce the efficiency of conducting clinical trials | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a P-value | |
| 650 | 4 | |a clinical trial | |
| 650 | 4 | |a sample size | |
| 650 | 4 | |a threshold | |
| 650 | 4 | |a trial design | |
| 700 | 1 | |a Ho, James C |e verfasserin |4 aut | |
| 700 | 1 | |a Wang, Xiaofei |e verfasserin |4 aut | |
| 700 | 1 | |a Lam, Wendy W |e verfasserin |4 aut | |
| 700 | 1 | |a Pang, Herbert H |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Journal of clinical and translational science |d 2017 |g 8(2024), 1 vom: 15., Seite e9 |w (DE-627)NLM271221658 |x 2059-8661 |7 nnns |
| 773 | 1 | 8 | |g volume:8 |g year:2024 |g number:1 |g day:15 |g pages:e9 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1017/cts.2023.699 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 8 |j 2024 |e 1 |b 15 |h e9 | ||